Dr. Gregory Cairncross is a Professor in the Department of Clinical Neurosciences at the University of Calgary. Dr. Cairncross is best known for contributions to neuro-oncology. He discovered that oligodendroglioma, a type of brain cancer, is sensitive to chemotherapy, and he and David Louis co-discovered a molecular marker of their drug sensitivity. Testing for this marker is used worldwide to diagnose and treat patients with oligodendroglioma. A trial led by Dr. Cairncross showed that patients with this genetic subtype of oligodendroglioma live twice as long when chemotherapy is a part of their initial therapy. His contributions to the understanding and treatment of brain cancer have been cited nearly 60,000 times.
Cairncross, J. Gregory
Fundamental Research
Professor
MD, FRCP(C)
Web Presence:
Biography
Area of Focus
- Modeling the initiation of Glioblastoma
Summary of Research
We have developed a mouse model of Glioblastoma (GBM) that mimics human GBM. The model is unique in that the earliest stages of the disease can be studied. We think this model can be used to develop early therapeutic interventions or preventative strategies for GBM.
Area Of Focus
- Modeling the initiation of Glioblastoma
Summary Of Research
We have developed a mouse model of Glioblastoma (GBM) that mimics human GBM. The model is unique in that the earliest stages of the disease can be studied. We think this model can be used to develop early therapeutic interventions or preventative strategies for GBM.